[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Inhibrx Biosciences Inc (INBX)

Inhibrx Biosciences Inc (INBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,486,465
  • Shares Outstanding, K 14,671
  • Annual Sales, $ 1,300 K
  • Annual Income, $ -140,060 K
  • EBIT $ -123 M
  • EBITDA $ -121 M
  • 60-Month Beta 3.88
  • Price/Sales 1,247.82
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 85.59% (+4.19%)
  • Historical Volatility 130.69%
  • IV Percentile 14%
  • IV Rank 3.33%
  • IV High 373.04% on 10/22/25
  • IV Low 75.69% on 01/30/26
  • Expected Move (DTE 23) 13.74 (13.17%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 19
  • Volume Avg (30-Day) 348
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 5,876
  • Open Int (30-Day) 7,117
  • Expected Range 90.52 to 118.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-2.50
  • Number of Estimates 1
  • High Estimate $-2.50
  • Low Estimate $-2.50
  • Prior Year $-1.85
  • Growth Rate Est. (year over year) -35.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
99.00 +4.89%
on 05/22/26
150.98 -31.22%
on 05/11/26
-25.21 (-19.54%)
since 04/24/26
3-Month
57.30 +81.23%
on 03/27/26
155.29 -33.13%
on 04/22/26
+26.61 (+34.46%)
since 02/26/26
52-Week
12.68 +719.29%
on 05/27/25
155.29 -33.13%
on 04/22/26
+90.99 (+707.50%)
since 05/23/25

Most Recent Stories

More News
Inhibrx Reports First Quarter 2026 Financial Results

SAN DIEGO , May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2026. The biopharmaceutical...

INBX : 105.76 (+4.38%)
Will INBX Continue Burning Cash While Markets Price In Miracles That Haven't Arrived?

Barchart Research What to Expect from INBX Earnings INBX Generated May 12, 2026 Current Price $108.65 EPS Estimate $$-2.37 Consensus Rating Moderate Buy Average Move 4.55% Will INBX Continue Burning Cash...

INBX : 105.76 (+4.38%)
Inhibrx Biosciences’ INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study

Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck’s KEYTRUDA in first-line PD-L1-positive head and neck squamous cell carcinoma, with...

INBX : 105.76 (+4.38%)
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

SAN DIEGO , May 11, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic...

INBX : 105.76 (+4.38%)
Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

– Event to be webcast live on Monday, May 11, 2026, at 5:30 a.m. PT –

INBX : 105.76 (+4.38%)
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

SAN DIEGO , April 21, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic...

INBX : 105.76 (+4.38%)
Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

– Event to be webcast live on Tuesday, April 21, 2026, at 1:30 p.m. PT –

INBX : 105.76 (+4.38%)
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

SAN DIEGO , March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2025. Following...

INBX : 105.76 (+4.38%)
Inhibrx Announces Participation in Upcoming Scientific Conference

SAN DIEGO , March 2, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic...

INBX : 105.76 (+4.38%)
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

SAN DIEGO , Dec. 16, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for...

INBX : 105.76 (+4.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Inhibrx Inc. is a clinical-stage biopharmaceutical company. It focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 120.80
2nd Resistance Point 115.97
1st Resistance Point 108.65
Last Price 105.76
1st Support Level 96.50
2nd Support Level 91.67
3rd Support Level 84.35

See More

52-Week High 155.29
Last Price 105.76
Fibonacci 61.8% 100.81
Fibonacci 50% 83.98
Fibonacci 38.2% 67.15
52-Week Low 12.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.